Eye drop and preparation method thereof

Abstract

The invention discloses an eye drop and a preparation method thereof, relating to an eye drop. The invention provides an eye drop with short action time, high purity and relatively good effect and capability of simultaneously playing a role of corneal neovascularization, lymphangiogenesis and cornea inflammation resistance and a preparation method thereof. The eye drop contains the following components by volume percent: 0.1-5% of bovine serum, 5-15% of thickening agent, 1-5% of acid-base regulating solution, 0.5-2% of antibiotics, 5-20% of recombinant protein and the balance of balanced saltsolution. The eye drop contains the balanced salt solution, the thickening agent, the bovine serum, the antibiotics, the acid-base regulating solution and the recombinant protein. The preparation method of the eye drop comprises the following steps of: adding the thickening agent, the bovine serum, the antibiotics and the recombinant protein to the balanced salt solution, regulating a pH value byusing the acid-base regulating solution and osmotic pressure by using an osmotic pressure buffering agent, and removing bacteria through membrane filtration; or preparing the bovine serum to sterile micropowder, dissolving the bovine serum into the balanced salt solution, regulating the pH value, removing the bacteria through the membrane filtration, and dissolving recombined powder into the solution so as to obtain the eye drop.

Description

Technical field [0001] The invention relates to an eye drop, in particular to an eye drop for treating corneal neovascularization, neo-lymphatic vessels, and corneal inflammatory diseases and a preparation method thereof. Background technique [0002] According to the World Health Organization report, corneal disease is the second major cause of vision loss. The number of new corneal blindness caused by corneal ulcers and eye trauma is 1.5 to 2 million every year, which seriously threatens the health of patients. In corneal diseases, the most important cause of blindness is corneal vascularization and scarring. At the same time, the limitation of therapeutic drugs is also a key issue. Corneal neovascularization and new lymphatic vessels can be secondary to a variety of corneal inflammatory diseases (keratitis, ulcers, etc.) and various corneal injuries (corneal trauma, burns, etc.). It is a combination of corneal irritation factors such as hypoxia and inflammation. The pathologi...

AI Technical Summary

Problems solved by technology

However, the function of Netrin family in normal cornea and inflammatory tissue has not yet been studied, and the mechanism is poorly understood. The attention of many ophthalmologists

[0004] At present, there are no anti-inflammatory, anti-neovascular and anti-lymphatic eye drops products on the market. Most ophthalmic drugs used in clinical practice have limited therapeutic functions, and there may be interactions and constraints among various drug components. Factors, plus the toxic ingredients and preservatives in various combined eye drops will damage the ocular surface microenvironment, make the existing ocular surface diseases worse, and bring certain confusion to the treatment of various corneal diseases; in addition , most anti-inflammatory products contain hormone ingredients, long-term use can seriously affect the ocular surface microenvironment of patients, some anti-inflammatory drugs have related complications such as large doses of chloramphenicol eye drops can cause eyelid and corneal edema , eye movement restriction and optic disc atrophy, long-term application can cause aplastic anemia, etc.; anti-neovascular drugs, such as artesunate (Chen Huanhuan, Zhou Huijun. Antiangiogenic effect of artesunate. Acta Pharmaceutica Sinica 2004, 39 (1): 29-33) eye drops, the composition is relatively complex, the effect is not sure enough, and it has no anti-inflammatory and anti-lymphatic effect; doxycycline eye drops is an effective drug for treating inflammation, but there is no official drug in my country at present. commercial formulation

Images